AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push
Bloomberg 12/13/2020
(Bloomberg)
AstraZeneca Plc, one of the drugmakers leading the fight against Covid-19, highlighted where its growth will come from after the pandemic with a $39 billion deal for rare-disease specialist Alexion Pharmaceuticals Inc.
The proposed cash-and-stock acquisition will add treatments for uncommon blood and immunological disorders to the portfolio of Cambridge, U.K.-based AstraZeneca, which had spent years paring away older and less profitable products to focus on cancer.
While the pandemic smothered economies and AstraZeneca entered a relatively low-return project to develop a Covid-19 vaccine with the University of Oxford, Chief Executive Officer Pascal Soriot kept his eyes downfield. After months of patients avoiding hospitals and clinics for fear of viral exposure, immunizations are coming online that promise to return society, and the drug industry, to some semblance of normal.
12 december 2020 kl 13:59
Greater scientific presence in immunology by adding Alexion s innovative complement-technology platforms and strong pipeline
Dedicated rare disease unit to be headquartered in Boston
Geographical presence to be enhanced with broad coverageacross primary, speciality and highly specialised care
Double-digit revenue growth through 2025; acquisition strengthens AstraZeneca s broad-based revenue and the company will further globalise Alexion s portfolio
Enhanced operating margin and cash flow to enable rapid debt reduction with an ambition to increase the dividend
The acquisition will be immediately core earnings-accretive andvalue-enhancing, and is aligned with stated capital-allocation priorities
AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion.
Press release content from Business Wire. The AP news staff was not involved in its creation.
AstraZeneca to Acquire Alexion, Accelerating the Company’s Strategic and Financial Development
December 12, 2020 GMT
CAMBRIDGE, England & BOSTON (BUSINESS WIRE) Dec 12, 2020
AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion.
Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share. Based on AstraZeneca’s reference average ADR price of $54.14, this implies total consideration to Alexion shareholders of $39bn or $175 per share.